14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $4.03 $5.34 Thursday, 25th Apr 2024 BCRX stock ended at $4.16. This is 1.19% less than the trading day before Wednesday, 24th Apr 2024. During the day the stock fluctuated 3.47% from a day low at $4.03 to a day high of $4.17.
90 days $4.03 $6.35
52 weeks $4.03 $9.07

Historical BioCryst Pharmaceuticals prices

Date Open High Low Close Volume
Aug 20, 2020 $4.33 $4.47 $4.28 $4.36 3 212 713
Aug 19, 2020 $4.51 $4.55 $4.37 $4.39 3 567 818
Aug 18, 2020 $4.51 $4.68 $4.44 $4.51 4 400 330
Aug 17, 2020 $4.31 $4.57 $4.23 $4.53 4 912 588
Aug 14, 2020 $4.55 $4.58 $4.25 $4.31 7 212 742
Aug 13, 2020 $4.33 $4.67 $4.23 $4.60 12 051 425
Aug 12, 2020 $3.99 $4.07 $3.92 $3.97 4 946 619
Aug 11, 2020 $4.13 $4.19 $3.92 $3.96 6 158 480
Aug 10, 2020 $4.00 $4.22 $3.95 $4.13 6 660 006
Aug 07, 2020 $4.00 $4.03 $3.81 $3.97 6 414 961
Aug 06, 2020 $4.00 $4.14 $3.86 $4.00 9 714 861
Aug 05, 2020 $4.23 $4.32 $4.09 $4.21 6 062 031
Aug 04, 2020 $4.46 $4.50 $4.21 $4.23 6 061 582
Aug 03, 2020 $4.42 $4.50 $4.16 $4.40 8 451 525
Jul 31, 2020 $4.22 $4.28 $4.02 $4.07 6 012 196
Jul 30, 2020 $4.12 $4.42 $4.11 $4.22 7 507 260
Jul 29, 2020 $4.43 $4.47 $4.16 $4.22 7 381 572
Jul 28, 2020 $4.53 $4.60 $4.39 $4.42 6 452 979
Jul 27, 2020 $4.50 $4.55 $4.40 $4.50 4 829 758
Jul 24, 2020 $4.49 $4.54 $4.33 $4.45 4 553 261
Jul 23, 2020 $4.81 $4.84 $4.48 $4.57 6 041 413
Jul 22, 2020 $4.92 $4.92 $4.70 $4.81 4 557 300
Jul 21, 2020 $5.11 $5.17 $4.83 $4.87 7 145 200
Jul 20, 2020 $5.10 $5.29 $5.02 $5.13 6 362 800
Jul 17, 2020 $5.02 $5.15 $4.98 $5.04 6 047 400
Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT